Federal officials gave the green light to a lifespan-extension drug for dogs, and the biotech company Loyal is behind it. The medication targets biological aging in larger breeds that usually die younger, making this the first FDA-backed treatment of its kind for animals. Scientists working on the project say the goal is to keep bigger dogs mobile and healthy for longer instead of creating some weird super-canine situation.
Loyal is pushing through the final approval stages, and dog owners might get their hands on the medication within a few years. The treatment works by messing with the pathways that control how quickly a dog's body deteriorates with age. For people who see their pets as family members, the possibility of extra years together has already kicked off a ton of discussion and hype online.
Loyal is pushing through the final approval stages, and dog owners might get their hands on the medication within a few years. The treatment works by messing with the pathways that control how quickly a dog's body deteriorates with age. For people who see their pets as family members, the possibility of extra years together has already kicked off a ton of discussion and hype online.
